Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for TG Therapeutics, Inc. (TGTX : NSDQ)
 
 • Company Description   
TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Number of Employees: 286

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.39 Daily Weekly Monthly
20 Day Moving Average: 2,555,479 shares
Shares Outstanding: 144.43 (millions)
Market Capitalization: $778.50 (millions)
Beta: 2.25
52 Week High: $41.00
52 Week Low: $4.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -27.36% -18.19%
12 Week -45.22% -39.79%
Year To Date -71.63% -61.16%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2 GANSEVOORT STREET 9TH FLOOR
-
NEW YORK,NY 10014
USA
ph: 212-554-4484
fax: 212-554-4531
ir@tgtxinc.com http://www.tgtherapeutics.com
 
 • General Corporate Information   
Officers
Michael S. Weiss - Chairman and Chief Executive Officer
Sean A. Power - Chief Financial Officer
Laurence N. Charney - Director
Yann Echelard - Director
Kenneth Hoberman - Director

Peer Information
TG Therapeutics, Inc. (BJCT)
TG Therapeutics, Inc. (CADMQ)
TG Therapeutics, Inc. (APNO)
TG Therapeutics, Inc. (UPDC)
TG Therapeutics, Inc. (IMTIQ)
TG Therapeutics, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 88322Q108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/01/22
Share - Related Items
Shares Outstanding: 144.43
Most Recent Split Date: 4.00 (0.02:1)
Beta: 2.25
Market Capitalization: $778.50 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/01/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.57
Price/Cash Flow: -
Price / Sales: 98.40
EPS Growth
vs. Year Ago Period: 26.09%
vs. Previous Quarter: 27.14%
Sales Growth
vs. Year Ago Period: 154.22%
vs. Previous Quarter: -13.14%
ROE
03/31/22 - -118.49
12/31/21 - -101.11
09/30/21 - -82.68
ROA
03/31/22 - -82.98
12/31/21 - -76.53
09/30/21 - -66.42
Current Ratio
03/31/22 - 4.43
12/31/21 - 5.06
09/30/21 - 4.24
Quick Ratio
03/31/22 - 4.43
12/31/21 - 5.06
09/30/21 - 4.24
Operating Margin
03/31/22 - -4,126.45
12/31/21 - -5,204.07
09/30/21 - -7,784.36
Net Margin
03/31/22 - -4,126.45
12/31/21 - -5,204.07
09/30/21 - -7,784.36
Pre-Tax Margin
03/31/22 - -4,126.47
12/31/21 - -5,204.08
09/30/21 - -7,784.36
Book Value
03/31/22 - 1.18
12/31/21 - 1.68
09/30/21 - 2.20
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.39
12/31/21 - 0.28
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 28.30
12/31/21 - 21.97
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©